Which has stronger earnings & valuation, NXTC or PMN?

Promis Neurosciences is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$8.70 N/A Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A

Is NXTC or PMN more profitable?

Promis Neurosciences' return on equity of -143.09% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -154.62% -100.19% Promis Neurosciences N/A -143.09% -109.15%

Is COYA or NXTC more profitable?

NextCure has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Coya Therapeutics -270.22% -52.05% -46.34% NextCure N/A -154.62% -100.19%

Is NXTC or GUTS more profitable?

NextCure's return on equity of -154.62% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -154.62% -100.19% Fractyl Health N/A -1,362.10% -84.89%

Does the media favor NXTC or GUTS?

In the previous week, Fractyl Health had 17 more articles in the media than NextCure. MarketBeat recorded 20 mentions for Fractyl Health and 3 mentions for NextCure. NextCure's average media sentiment score of 0.96 beat Fractyl Health's score of 0.11 indicating that NextCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fractyl Health 0 Very Positive mention(s) 0 Positive mention(s) 18 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, NXTC or GNLX?

Genelux has higher revenue and earnings than NextCure. Genelux is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$8.70 N/A Genelux $10K 11,490.96 -$32.15M -$0.86 N/A

Is NXTC or GNLX more profitable?

NextCure's return on equity of -154.62% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -154.62% -100.19% Genelux N/A -205.85% -138.79%

Does the media prefer NXTC or GNLX?

In the previous week, NextCure and NextCure both had 3 articles in the media. NextCure's average media sentiment score of 0.96 beat Genelux's score of 0.54 indicating that NextCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NXTC or ONCY?

Oncolytics Biotech is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$8.70 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A

Is NXTC or ONCY more profitable?

NextCure's return on equity of -154.62% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -154.62% -100.19% Oncolytics Biotech N/A -2,185.97% -442.99%

Does the media prefer NXTC or ONCY?

In the previous week, Oncolytics Biotech had 1 more articles in the media than NextCure. MarketBeat recorded 4 mentions for Oncolytics Biotech and 3 mentions for NextCure. NextCure's average media sentiment score of 0.96 beat Oncolytics Biotech's score of 0.57 indicating that NextCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

NextCure (NXTC) Competitors

$6.64 -0.36 (-5.14%)

Closing price 04:00 PM Eastern

Extended Trading

$6.71 +0.07 (+1.04%)

As of 07:30 PM Eastern

Compare

NXTC vs. PMN, COYA, GUTS, GNLX, and ONCY

Should you buy NextCure stock or one of its competitors? NextCure's main competitors and comparable companies include Promis Neurosciences (PMN), Coya Therapeutics (COYA), Fractyl Health (GUTS), Genelux (GNLX), and Oncolytics Biotech (ONCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NextCure compare to Promis Neurosciences?

NextCure (NASDAQ:NXTC) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Promis Neurosciences is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

NextCure presently has a consensus price target of $19.00, indicating a potential upside of 186.14%. Promis Neurosciences has a consensus price target of $34.00, indicating a potential upside of 156.41%. Given NextCure's higher probable upside, analysts plainly believe NextCure is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Promis Neurosciences' return on equity of -143.09% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-154.62%	-100.19%
Promis Neurosciences	N/A	-143.09%	-109.15%

NextCure has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

42.7% of NextCure shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 11.9% of NextCure shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, NextCure had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for NextCure and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 1.89 beat NextCure's score of 0.96 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
NextCure	Positive
Promis Neurosciences	Very Positive

Summary

Promis Neurosciences beats NextCure on 8 of the 14 factors compared between the two stocks.

How does NextCure compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Coya Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, NextCure has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

NextCure has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
NextCure	N/A	-154.62%	-100.19%

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Coya Therapeutics has higher revenue and earnings than NextCure. Coya Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.69	-$21.23M	-$1.07	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

Coya Therapeutics presently has a consensus target price of $15.33, indicating a potential upside of 230.46%. NextCure has a consensus target price of $19.00, indicating a potential upside of 186.14%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Coya Therapeutics is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, NextCure had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 3 mentions for NextCure and 1 mentions for Coya Therapeutics. NextCure's average media sentiment score of 0.96 beat Coya Therapeutics' score of 0.94 indicating that NextCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Coya Therapeutics	Positive
NextCure	Positive

Summary

Coya Therapeutics beats NextCure on 8 of the 15 factors compared between the two stocks.

How does NextCure compare to Fractyl Health?

NextCure (NASDAQ:NXTC) and Fractyl Health (NASDAQ:GUTS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Fractyl Health had 17 more articles in the media than NextCure. MarketBeat recorded 20 mentions for Fractyl Health and 3 mentions for NextCure. NextCure's average media sentiment score of 0.96 beat Fractyl Health's score of 0.11 indicating that NextCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fractyl Health	0 Very Positive mention(s)	0 Positive mention(s)	18 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NextCure has higher earnings, but lower revenue than Fractyl Health. NextCure is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A
Fractyl Health	$90K	1,078.89	-$140.95M	-$0.88	N/A

NextCure has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market.

42.7% of NextCure shares are held by institutional investors. 11.9% of NextCure shares are held by insiders. Comparatively, 8.4% of Fractyl Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NextCure's return on equity of -154.62% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-154.62%	-100.19%
Fractyl Health	N/A	-1,362.10%	-84.89%

NextCure presently has a consensus price target of $19.00, indicating a potential upside of 186.14%. Fractyl Health has a consensus price target of $5.50, indicating a potential upside of 801.64%. Given Fractyl Health's stronger consensus rating and higher possible upside, analysts clearly believe Fractyl Health is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Fractyl Health beats NextCure on 9 of the 14 factors compared between the two stocks.

How does NextCure compare to Genelux?

NextCure (NASDAQ:NXTC) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Genelux has higher revenue and earnings than NextCure. Genelux is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A
Genelux	$10K	11,490.96	-$32.15M	-$0.86	N/A

NextCure has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Genelux has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

NextCure presently has a consensus target price of $19.00, indicating a potential upside of 186.14%. Genelux has a consensus target price of $18.00, indicating a potential upside of 608.66%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

NextCure's return on equity of -154.62% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-154.62%	-100.19%
Genelux	N/A	-205.85%	-138.79%

42.7% of NextCure shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, NextCure and NextCure both had 3 articles in the media. NextCure's average media sentiment score of 0.96 beat Genelux's score of 0.54 indicating that NextCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

NextCure beats Genelux on 7 of the 13 factors compared between the two stocks.

How does NextCure compare to Oncolytics Biotech?

NextCure (NASDAQ:NXTC) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

42.7% of NextCure shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NextCure has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

NextCure's return on equity of -154.62% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-154.62%	-100.19%
Oncolytics Biotech	N/A	-2,185.97%	-442.99%

In the previous week, Oncolytics Biotech had 1 more articles in the media than NextCure. MarketBeat recorded 4 mentions for Oncolytics Biotech and 3 mentions for NextCure. NextCure's average media sentiment score of 0.96 beat Oncolytics Biotech's score of 0.57 indicating that NextCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

NextCure currently has a consensus price target of $19.00, indicating a potential upside of 186.14%. Oncolytics Biotech has a consensus price target of $5.00, indicating a potential upside of 515.23%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Oncolytics Biotech is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

Summary

NextCure beats Oncolytics Biotech on 8 of the 14 factors compared between the two stocks.

Get NextCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXTC vs. The Competition

Export

Metric	NextCure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.29M	$3.86B	$7.15B	$13.98B
Dividend Yield	N/A	3.66%	2.57%	11.70%
P/E Ratio	-0.76	14.33	272.99	25.37
Price / Sales	N/A	1,295.87	602.82	70.35
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	0.67	15.26	10.43	6.24
Net Income	-$55.84M	-$22.78M	$3.49B	$358.08M
7 Day Performance	-15.09%	-2.03%	-2.11%	-1.43%
1 Month Performance	-19.12%	2.10%	0.64%	-2.71%
1 Year Performance	25.40%	42.58%	24.61%	8.46%

NextCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXTC NextCure	4.1626 of 5 stars	$6.64 -5.1%	$19.00 +186.1%	+32.2%	$25.29M	N/A	N/A	90	Short Interest Decrease Gap Down
PMN Promis Neurosciences	3.9465 of 5 stars	$12.53 -0.6%	$34.00 +171.3%	+23.3%	$112.99M	N/A	N/A	5	Positive News Gap Down
COYA Coya Therapeutics	2.1334 of 5 stars	$4.61 -3.2%	$15.33 +232.6%	-27.6%	$111.66M	$7.95M	N/A	6
GUTS Fractyl Health	3.1199 of 5 stars	$0.69 -1.6%	$5.50 +702.7%	-37.3%	$110.89M	$90K	N/A	102
GNLX Genelux	1.9145 of 5 stars	$2.54 +4.1%	$18.00 +608.7%	-37.0%	$110.40M	$10K	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXTC) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NextCure (NXTC) Competitors

NXTC vs. PMN, COYA, GUTS, GNLX, and ONCY

How does NextCure compare to Promis Neurosciences?

Summary

How does NextCure compare to Coya Therapeutics?

Summary

How does NextCure compare to Fractyl Health?

Summary

How does NextCure compare to Genelux?

Summary

How does NextCure compare to Oncolytics Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NextCure (NXTC) Competitors

NXTC vs. PMN, COYA, GUTS, GNLX, and ONCY

How does NextCure compare to Promis Neurosciences?

Which has stronger earnings & valuation, NXTC or PMN?

Do analysts prefer NXTC or PMN?

Is NXTC or PMN more profitable?

Which has more volatility & risk, NXTC or PMN?

Do institutionals & insiders believe in NXTC or PMN?

Does the media favor NXTC or PMN?

Summary

How does NextCure compare to Coya Therapeutics?

Which has more volatility & risk, COYA or NXTC?

Is COYA or NXTC more profitable?

Do institutionals and insiders believe in COYA or NXTC?

Which has better valuation and earnings, COYA or NXTC?

Do analysts recommend COYA or NXTC?

Does the media prefer COYA or NXTC?

Summary

How does NextCure compare to Fractyl Health?

Does the media favor NXTC or GUTS?

Which has preferable valuation and earnings, NXTC or GUTS?

Which has more risk & volatility, NXTC or GUTS?

Do insiders and institutionals believe in NXTC or GUTS?

Is NXTC or GUTS more profitable?

Do analysts rate NXTC or GUTS?

Summary

How does NextCure compare to Genelux?

Which has preferable earnings and valuation, NXTC or GNLX?

Which has more volatility and risk, NXTC or GNLX?

Do analysts rate NXTC or GNLX?

Is NXTC or GNLX more profitable?

Do institutionals and insiders believe in NXTC or GNLX?

Does the media prefer NXTC or GNLX?

Summary

How does NextCure compare to Oncolytics Biotech?

Do institutionals & insiders believe in NXTC or ONCY?

Which has more risk & volatility, NXTC or ONCY?

Is NXTC or ONCY more profitable?

Does the media prefer NXTC or ONCY?

Do analysts rate NXTC or ONCY?

Which has stronger valuation and earnings, NXTC or ONCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools